+1-888-308-5802     
News Contact Us

Britain nears USD 625 million COVID-19 vaccine deals with Sanofi/GSK

Author : Pankaj Singh | Published Date : 2020-07-06 

With over 100 vaccines are being tested and developed to stop the spread of COVID-19, it seems that governments worldwide are racing to secure supplies of vaccines even before their efficiency is proven. As per the latest news, Britain government is close to a USD 625 million supply deals with Sanofi S.A. and GlaxoSmithKline plc for 60 million doses of potential COVID-19 vaccine.

Sources cite that the agreement with GSK and Sanofi would be Britain’s second such deal after it said it would purchase 100 million doses of the Oxford-AstraZeneca vaccine. The government authorities in the UK are actively engaging with several companies both abroad and the UK to negotiate access to vaccines, a spokesperson from Britain’s business ministry, said without revealing the names of companies.

Sanofi is currently working on two potential COVID-19 vaccines, one of which usez an adjuvant made by GSK to boost its efficacy. The company has also said that it can develop up to 1 billion doses annually. The clinical trials of vaccines are expected to commence in September and Sanofi expects to get approval by the first half of 2021, sooner than previously expected.

However, its timeline for human clinical trials is much behind the likes of the Oxford University in collaboration with AstraZeneca Plc, Moderna Inc, and an alliance of Pfizer Inc and BioNTech. The projects of these companies have grabbed headlines by entering into human trials in early March.

Sanofi has also received financial backing from America. The European Union (EU) is also looking for a deal with Sanofi and has requested Britain to join its efforts to purchase vaccines for the bloc.

Meanwhile, both Sanofi and GSK did not respond to request for comment. Both firms have said that they are focusing on quality over speed in developing vaccines.

Source Credit - https://uk.reuters.com/article/uk-health-coronavirus-britain-sanofi/britain-nears-625-million-sanofi-gsk-covid-19-vaccine-deal-report-idUKKBN24606I

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

MAS grants SRFB privileges to StanChart under improved framework

Published Date: 2020-08-03         Author: Pankaj Singh

The Monetary Authority of Singapore (MAS), Singapore’s financial and central bank authority has reportedly awarded SRFB (Significantly Rooted Foreign Bank) privileges to Standard Chartered Singapore, which allows the bank to operate in additional places of business. The agency said in the p... Read More

Grofers records profitable growth, plans IPO listing in late 2021

Published Date: 2020-07-27         Author: Pankaj Singh

The COVID-19 pandemic has managed to stall numerous businesses worldwide. However, online grocery delivery firms have managed to amass considerable revenue growth over the months as a result of stern lockdown norms that have ensued consumers to opt for online food & grocery services. Indian o... Read More

U.S. to invest $1.95 billion in Pfizer & BioNTech for COVID-19 vaccine

Published Date: 2020-07-24         Author: Pankaj Singh

As the COVID-29 pandemic surges on, the Trump administration has reportedly invested nearly $2 billion in a new coronavirus vaccine contract with Pfizer and German pharma company BioNTech to produce mor than 100 million vaccine doses by the end of the year. The U.S. government plans to administer 50... Read More

© 2020 Fractovia. All Rights Reserved